Home/Filings/4/0001638599-19-000935
4//SEC Filing

Isett Thomas Francis 3rd 4

Accession 0001638599-19-000935

CIK 0001420720other

Filed

Nov 4, 7:00 PM ET

Accepted

Nov 5, 12:40 PM ET

Size

13.1 KB

Accession

0001638599-19-000935

Insider Transaction Report

Form 4
Period: 2019-10-29
Transactions
  • Purchase

    Series B Warrants (Right to Buy)

    2019-10-29$1000.00/sh+100,000$100,000,000350,000 total
    Exercise: $0.22From: 2019-10-29Exp: 2026-10-29Common Stock (100,000 underlying)
  • Purchase

    Series C Convertible Preferred Stock

    2019-10-29$1000.00/sh+20$20,000350,000 total
    Exercise: $0.20Common Stock (100,000 underlying)
  • Purchase

    Series A Warrants (Right to Buy)

    2019-10-29$1000.00/sh+100,000$100,000,000350,000 total
    Exercise: $0.22From: 2019-10-29Exp: 2021-10-29Common Stock (100,000 underlying)
Footnotes (9)
  • [F1]The shares of Series C Convertible Preferred Stock, $0.001 par value (the "Series C Preferred Shares"), were acquired by Mr. Isett in a public offering by iBio, Inc. ("iBio").
  • [F2]Each Series C Preferred Share has a stated value of $1,000 and is convertible into shares of iBio's common stock at any time and from time to time at the option of the holder at a price of $0.20 per share, subject to adjustment as provided in the Certificate of Designation of Preferences, Rights and Limitations of the Series C Convertible Preferred Stock, provided that the Series C Preferred Shares may not be converted if the holder, together with the holder's affiliates, would beneficially own over 4.99% (which may be increased up to 9.99% upon election by the holder on 61 days' notice) of iBio's outstanding common stock at the time of conversion.
  • [F3]The Series C Preferred Shares have no expiration date.
  • [F4]Each of Series C Preferred Share was sold together with Series A Warrants to purchase one share of common stock for each share of common stock issuable upon conversion of the Series C Preferred Share and Series B Warrants to purchase one share of common stock for each share of common stock issuable upon conversion of the Series C Preferred Share. Each Series C Preferred Share and accompanying Series A Warrants and Series B Warrants was sold at a combined public offering price of $1,000.
  • [F5]Reflects number of securities beneficially owned following all transactions reported on this Form 4, on an as converted to common stock basis.
  • [F6]The Series A Warrants were acquired by Mr. Isett in a public offering by iBio.
  • [F7]The Series A Warrants were sold together with Series C Preferred Shares and Series B Warrants in the public offering. Each of Series C Preferred Share was sold together with Series A Warrants to purchase one share of common stock for each share of common stock issuable upon conversion of the Series C Preferred Share and Series B Warrants to purchase one share of common stock for each share of common stock issuable upon conversion of the Series C Preferred Share. Each Series C Preferred Share and accompanying Series A Warrants and Series B Warrants was sold at a combined public offering price of $1,000.
  • [F8]The Series B Warrants were acquired by Mr. Isett in a public offering by iBio.
  • [F9]The Series B Warrants were sold together with Series C Preferred Shares and Series A Warrants in the public offering. Each of Series C Preferred Share was sold together with Series A Warrants to purchase one share of common stock for each share of common stock issuable upon conversion of the Series C Preferred Share and Series B Warrants to purchase one share of common stock for each share of common stock issuable upon conversion of the Series C Preferred Share. Each Series C Preferred Share and accompanying Series A Warrants and Series B Warrants was sold at a combined public offering price of $1,000.

Issuer

iBio, Inc.

CIK 0001420720

Entity typeother

Related Parties

1
  • filerCIK 0001773100

Filing Metadata

Form type
4
Filed
Nov 4, 7:00 PM ET
Accepted
Nov 5, 12:40 PM ET
Size
13.1 KB